Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
305.98
-8.12 (-2.59%)
Sep 29, 2026, 11:42 AM EDT - Market open
Ligand Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,100 | 3,721 | 2,025 | 1,245 | 1,128 | 2,581 | |
Market Cap Growth | 83.41% | 83.80% | 62.59% | 10.35% | -56.28% | 61.40% |
Enterprise Value | 5,874 | 3,508 | 1,812 | 1,061 | 1,121 | 2,589 |
Last Close Price | 314.10 | 189.07 | 107.15 | 71.42 | 66.80 | 99.67 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 33.28 | 29.90 | - | 23.88 | - | 45.18 |
Forward PE | 44.34 | 35.20 | 53.58 | 35.07 | 298.37 | 298.37 |
PS Ratio | 21.42 | 13.88 | 12.11 | 9.48 | 5.75 | 10.69 |
PB Ratio | 6.47 | 3.66 | 2.44 | 1.78 | 1.89 | 3.14 |
P/TBV Ratio | 9.48 | 5.39 | 4.42 | 4.18 | 8.11 | 7.85 |
P/FCF Ratio | 47.35 | 76.09 | 21.26 | 27.04 | 8.99 | 36.86 |
P/OCF Ratio | 47.25 | 75.39 | 20.86 | 25.12 | 8.19 | 32.76 |
PEG Ratio | 1.87 | 2.42 | 3.57 | 2.34 | 23.42 | 18.19 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 20.64 | 13.08 | 10.84 | 8.08 | 5.71 | 10.72 |
EV/EBITDA Ratio | 45.09 | 43.32 | 31.11 | 22.90 | 27.11 | 22.09 |
EV/EBIT Ratio | 59.91 | 74.32 | 78.73 | 108.04 | 369.11 | 39.07 |
EV/FCF Ratio | 45.63 | 71.72 | 19.03 | 23.04 | 8.93 | 36.96 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.17 | 0.44 | 0.01 | 0.01 | 0.15 | 0.40 |
Debt / EBITDA Ratio | 8.46 | 5.52 | 0.12 | 0.13 | 2.09 | 2.74 |
Debt / FCF Ratio | 8.61 | 9.23 | 0.08 | 0.13 | 0.70 | 4.63 |
Net Debt / Equity Ratio | -0.23 | -0.28 | -0.30 | -0.23 | -0.21 | -0.02 |
Net Debt / EBITDA Ratio | -1.70 | -3.48 | -4.27 | -3.54 | -3.00 | -0.14 |
Net Debt / FCF Ratio | -1.72 | -5.77 | -2.61 | -3.56 | -0.99 | -0.24 |
Asset Turnover | 0.19 | 0.21 | 0.19 | 0.17 | 0.19 | 0.18 |
Inventory Turnover | 4.24 | 8.24 | 1.71 | 1.88 | 4.38 | 3.50 |
Quick Ratio | 30.83 | 21.83 | 8.32 | 12.49 | 2.50 | 10.39 |
Current Ratio | 31.18 | 22.23 | 8.93 | 14.15 | 2.67 | 11.15 |
Return on Equity (ROE) | 21.96% | 13.47% | -0.53% | 8.29% | -0.74% | 9.98% |
Return on Assets (ROA) | 3.99% | 2.36% | 1.66% | 0.79% | 0.18% | 3.11% |
Return on Invested Capital (ROIC) | 11.76% | 5.61% | -6.59% | 1.64% | -0.07% | 8.50% |
Return on Capital Employed (ROCE) | 4.70% | 3.10% | 2.50% | 1.30% | 0.50% | 5.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.17% | 3.34% | -0.20% | 4.19% | -2.96% | 2.21% |
FCF Yield | 2.11% | 1.31% | 4.70% | 3.70% | 11.12% | 2.71% |
Buyback Yield / Dilution | -12.96% | -10.96% | -3.00% | -5.27% | 2.19% | -2.50% |